

Press Release:

**Indivumed and EXACT Sciences enter pioneering research material agreement
for colon cancer program**

Hamburg, Germany – July 10th, 2003 - Indivumed GmbH, Center for Cancer Research at the Israelitisches Krankenhaus in Hamburg, has entered a unique materials supply agreement with EXACT Sciences Corporation, a global leader in applying advances in the field of genomics to facilitate early detection of cancer. Under this agreement, EXACT Sciences will have access to Indivumed's unique human tissue/fluid and data bank for its colon cancer research program.

“For the efficient development of new human diagnostics, excellent clinical samples together with comprehensive clinical data are prerequisite. Access to Indivumed's clinical sample and data bank will be important to our ability to discover novel methods and tools to detect colon cancer,” said Dr. Michael E. Ross, Vice President for Clinical Affairs of EXACT Sciences.

“Indivumed promotes individualized treatment modalities for cancer therapy and the development of novel tumor diagnostics,” said Dr. Hartmut Juhl, CEO of Indivumed. “This agreement is a step in the right direction. The utilization of high quality preparations of clinical samples will provide EXACT Sciences with an important resource as the company continues its applied genomics research in the development of novel DNA-based diagnostics.

About Indivumed

Indivumed GmbH, Center for Cancer Research at the Israelitisches Krankenhaus, is based in Hamburg, Germany (www.indivumed.com). The company has established a premier resource for medical research, a unique human tissue and fluid bank with comprehensive clinical data. The direct access to clinical samples in a growing network of leading oncological hospitals allows the company to obtain preparations of clinical samples of exceptional quality together with comprehensive, corresponding clinical data. Research, sample and clinical information are stored and accessible in a comprehensive data bank, indivuNET™, which was created specifically in order to meet the current and future needs of the medical research community.

About EXACT Sciences Corporation

EXACT Sciences Corporation is an applied genomics company that has developed proprietary technologies that may be used for the early detection of several common cancers. EXACT Sciences has selected colorectal cancer as the first application of its technologies. Colorectal cancer is the most deadly cancer among non-smokers, and is curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than 20 years, the rate of early detection of colorectal cancer remains low. EXACT Sciences believes its genomics-based technologies will enable early detection of colorectal cancer so that more people can be effectively treated. Founded in 1995, EXACT Sciences is based in Marlborough, MA, U.S.A. Detailed information on EXACT Sciences can be found on the World Wide Web at www.EXACTsciences.com.

For further information about Indivumed please contact:

Hartmut Juhl, MD PhD
CEO
Indivumed GmbH
Center for Cancer Research at the Israelitisches Krankenhaus in Hamburg
(49) 40 413383-10
Email: juhl@indivumed.com